Samsung Bioepis signs Teva partnership for SB41, SB44 biosimilars development and commercialization
Bitget2026/10/01 09:02- Samsung Bioepis signed an early-stage partnership with Teva to develop SB41 and SB44 biosimilars for commercialization.
- Bioepis will handle development, manufacturing, supply; Teva will lead sales in the US, Europe, Canada.
- Agreement signed Sept. 30, 2026; contract term and value were not disclosed.
- Bioepis expects receipts of at least KRW 41.8 billion, based on a 2.5% disclosure threshold versus 2025 financials.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Hong Kong live music service provider Guitar Group applies for US IPO, aiming to raise $31 million
Guitar Group, a provider of music performance events, guitar-making workshops, and guitar repair services, submitted an application to the U.S. Securities and Exchange Commission (SEC) on Thursday, seeking to raise up to $31 million through an initial public offering (IPO).
Texas Election Reversal: Musk Empire Plummets by $380 billions After Hours
The victory of the Democratic Party in Texas has raised concerns about a pause in data center construction. Tesla shares rose slightly by 0.58% after hours to $345.70, but the market value of Musk's companies has evaporated by over $380 billions this week, with regulatory risks intensifying.
Indian Rupee: Higher inflation supports rate hike bets – DBS
Bitcoin closed above the 50-week moving average on Thursday.
Crypto prices
More
